Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Michael Mauro, Alexis Visotcky, Kathryn E Flynn, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Jorge E. Cortes, Vamsi K Kota, Srinivas K. Tantravahi, Arielle Baim, Mei-Jie Zhang, Alexander Hinman, Ehab L. Atallah, Kendra Sweet

Blood (2022) 140 (Supplement 1): 6765–6766.

https://doi.org/10.1182/blood-2022-160138

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

Journal Articles

Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

Irena Tan, Rachel Cusatis, Emma Crawford, Aline Thiengmany, Claire Piehowski, Idayat Akinola, Juliana Craig, Sheila Lahijani, Matthew J. Frank, Nirav N. Shah, Anita D'Souza, David B. Miklos, Lori Muffly, Kathryn E Flynn, Surbhi Sidana

Blood (2021) 138 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2021-145746

Published: 2021

Journal Articles

Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study

Rachel Cusatis, Irena Tan, Claire Piehowski, Idayat Akinola, Emma Crawford, Juliana Craig, Aline Thiengmany, Matthew J. Frank, David B. Miklos, Nirav N. Shah, Anita D'Souza, Jennifer M Knight, Lori Muffly, Kathryn E Flynn, Surbhi Sidana

Blood (2021) 138 (Supplement 1): 567.

https://doi.org/10.1182/blood-2021-146032

Published: 2021

Journal Articles

Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome

Rachel Cusatis, Michael Martens, Ryotaro Nakamura, Corey Cutler, Wael Saber, Stephanie J. Lee, Brent R. Logan, Bronwen E. Shaw, Mary M. Horowitz, Kathryn E Flynn

Blood (2021) 138 (Supplement 1): 421.

https://doi.org/10.1182/blood-2021-147514

Published: 2021

Journal Articles

Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Kendra Sweet, Ehab L. Atallah, Jerry P. Radich, Mei-Jie Zhang, Eva Sahakian, Melanie Mediavilla-Varela, Alexis Vistocky, Michael C. Heinrich, James E. Thompson, Michael J. Mauro, Kathryn E Flynn, Arielle Baim, Javier Pinilla Ibarz

Blood (2021) 138 (Supplement 1): 2555.

https://doi.org/10.1182/blood-2021-147954

Published: 2021

Journal Articles

Building a National CML Registry

Ehab L. Atallah, MD, Arun K Singavi, MD, Bradley Taylor, Arielle Baim, Judith Myers, Emily Giever, Joan Neuner, MD, Bronwen E. Shaw, MD PhD, Kathryn E Flynn, PhD

Blood (2019) 134 (Supplement_1): 3440.

https://doi.org/10.1182/blood-2019-130358

Published: 2019

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Merav Bar, MD, Julia Ruark, MD MPH, Erin Mullane, DNP, Nancy Cleary, BSc, Ana Cordeiro, MD, Evandro D. Bezerra, MD, Jenna M. Voutsinas, MPH, Bronwen E. Shaw, MD PhD, Qian Vicky Wu, PhD, Kathryn E Flynn, PhD, Stephanie J. Lee, MD MPH, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Jesse Fann

Blood (2019) 134 (Supplement_1): 4453.

https://doi.org/10.1182/blood-2019-122755

Published: 2019

Journal Articles

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Anita D'Souza, MBBS, Kathryn E Flynn, PhD, Binod Dhakal, MBBS, Saurabh Chhabra, MD, Marcelo C Pasquini, MDMS, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2018-99-114783

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

NARROW

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study

Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome

Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Building a National CML Registry

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only